Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Feb/Mar:41 Suppl 2S:S35-S57.
doi: 10.1097/DBP.0000000000000770.

Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder

William J Barbaresi  1 , Lisa Campbell  2 , Elizabeth A Diekroger  3 , Tanya E Froehlich  4 , Yi Hui Liu  5 , Eva O'Malley  6 , William E Pelham Jr  7 , Thomas J Power  8 , Samuel H Zinner  9 , Eugenia Chan  1
Affiliations
Practice Guideline

Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder

William J Barbaresi et al. J Dev Behav Pediatr. 2020 Feb/Mar.

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is the most common childhood neurodevelopmental disorder and is associated with an array of coexisting conditions that complicate diagnostic assessment and treatment. ADHD and its coexisting conditions may impact function across multiple settings (home, school, peers, community), placing the affected child or adolescent at risk for adverse health and psychosocial outcomes in adulthood. Current practice guidelines focus on the treatment of ADHD in the primary care setting. The Society for Developmental and Behavioral Pediatrics has developed this practice guideline to facilitate integrated, interprofessional assessment and treatment of children and adolescents with "complex ADHD" defined by age (<4 years or presentation at age >12 years), presence of coexisting conditions, moderate to severe functional impairment, diagnostic uncertainty, or inadequate response to treatment.

PubMed Disclaimer

References

    1. The Society for Developmental & Behavioral Pediatrics (SDBP). 2019. Available at: http://sdbp.org/about-us/index.cfm. Accessed July 1, 2019.
    1. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr. 2007;28:265–273.
    1. Chang Z, Lichtenstein P, Langström N, et al. Association between prescription of major psychotropic medications and violent reoffending after prison release. JAMA. 2016;316:1798–1807.
    1. Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit–hyperactivity disorder and criminality. N Engl J Med. 2012;367:2006–2014.
    1. Chang Z, D'Onofrio BM, Quinn PD, et al. Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry. 2016;80:916–922.

Publication types